CJC-1295 (No-DAC)

CJC-1295, a long-acting analog of growth hormone releasing hormone, produces sustained increases in growth hormone and insulin-like growth factor 1^[1]

This research study evaluated a sustained-release formulation of a GHRH analog (structurally related to CJC-1295) in healthy adult volunteers across single and multiple concentration cohorts. GH area-under-curve increased 2- to 10-fold over baseline following a single administration, with IGF-1 levels rising 1.5- to 3-fold above baseline within three days. The compound demonstrated a half-life markedly longer than unmodified GHRH, attributed to albumin binding via a maleimide-thiol conjugate. No serious adverse events were recorded; mild transient flushing and injection site reactions were the most commonly reported effects.

Last verified: 2026-04-03

DPP-IV resistance and pulsatile GH release: pharmacokinetic characterization of modified GHRH analogs in rodent models^[2]

This preclinical pharmacokinetic study characterized the plasma stability and GH-releasing activity of modified GHRH(1-29) analogs with substitutions at positions 2, 8, 15, and 27 -- the same substitution pattern present in CJC-1295 No DAC. DPP-IV cleavage assays confirmed that the D-Ala2 substitution completely abolished DPP-IV activity at the Ala-Ile cleavage site, extending half-life from under two minutes (unmodified GHRH) to approximately 30 minutes in rat plasma. GH pulse analysis demonstrated physiologically patterned release consistent with normal somatotroph function, without sustained GH elevation between pulses.

Last verified: 2026-04-03